Shanghai Yaxin Biotechnology Co., Ltd. was established in 2008, a high-tech enterprise underChina National Biotec Group Company Limited (CNBG) of China National PharmaceuticalGroup Co., Ltd.(Sinopharm), focusing on R&D and production of animal-free sourced biopharmaceutical enzymes. lt is one of the drafters and formulators of the "Recombinant Trypsin Standard" of the 2020 edition of “Chinese Pharmacopoeia", and supplier of key rawmaterials in biomedicine market in China.
more >
Year of Establishment:
2008
Total Assets(USD):
less than 500,000
Total Number of Staff:
50 to 59
Main Competitive Advantages:
International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production capacity,Large Product Line,Small Orders Accepted,Reputation,Quality Service
Other Competitive Advantages:
Recombinant Products; Animal component-free of high purity, convenience and safety
Patents and Copyrights:
Business Type:
Manufacturer,Distributor
R&D capacity:
Annual Turnover(USD):
less than 500,000
Main Sales Markets:
North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Other Competitive Advantages:
Recombinant Products; Animal component-free of high purity, convenience and safety
Patents and Copyrights: